A Phase 1 SAD and MAD dose clinical trial of ZB021 in healthy volunteers
Latest Information Update: 29 May 2026
At a glance
- Drugs ZB 021 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
Most Recent Events
- 13 May 2026 According to Zenas BioPharma media release, Phase 1 SAD and MAD data expected by year-end 2026.
- 13 May 2026 According to Zenas BioPharma media release, first patient has been dosed in this trial.
- 13 May 2026 Status changed from planning to recruiting.